Affiliation: University of Oslo
- Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)Nikolaj Kunøe
Norwegian Centre for Addiction Research, University of Oslo, PO Box 1039, Blindern, N 0315, Oslo, Norway
BMC Pharmacol Toxicol 17:18. 2016..While XR-NTX has shown promise compared to placebo and daily naltrexone tablets, there is limited information on long-term safety and its performance compared to daily maintenance treatment...
- Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trialNikolaj Kunøe
Norwegian Centre for Addiction Research, Kirkeveien 166, Oslo NO 0407, Norway
Br J Psychiatry 194:541-6. 2009..Naltrexone has considerable potential in helping to prevent relapse in heroin dependency. A longer-lasting formulation for naltrexone treatment is desirable to further reduce non-adherence and relapse during treatment of opiate dependence...
- Retention in naltrexone implant treatment for opioid dependenceNikolaj Kunøe
Norwegian Centre for Addiction Research, Kirkeveien, Oslo, Norway
Drug Alcohol Depend 111:166-9. 2010..Sustained release naltrexone seems promising in reducing opioid use, but the extent to which patients remain in treatment beyond the first dosage of naltrexone is not clear...
- Challenges to antagonist blockade during sustained-release naltrexone treatmentNikolaj Kunøe
SERAF, Norwegian Centre for Addiction Research, Kirkeveien 166, 0407 Oslo, Norway
Addiction 105:1633-9. 2010....
- Naltrexone implants compared to methadone: outcomes six months after prison releasePhilipp P Lobmaier
Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway
Eur Addict Res 16:139-45. 2010..Methadone maintenance treatment has been shown to reduce heroin use, criminality and mortality. Naltrexone implant treatment has not previously been evaluated in prison settings...
- Interest in Extended Release Naltrexone among Opioid UsersKamni Sharma Haase
Norwegian Centre for Addiction Research SERAF, Oslo, Norway
Eur Addict Res 22:301-305. 2016..Therefore, we wanted to investigate opioid users' interest in antagonist treatment with naltrexone, administered as extended release injection, which supports abstinence by blocking illicit opioids for 4-5 weeks per administration...
- Injectable and implantable sustained release naltrexone in the treatment of opioid addictionNikolaj Kunøe
The Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway Oslo University Hospital, Oslo, Norway
Br J Clin Pharmacol 77:264-71. 2014..The literature suggests that sustained release naltrexone is a feasible, safe and effective option for assisting abstinence efforts in opioid addiction. ..